CUMBERLAND PHARMACEUTICALS INC Q3 FY2024 earnings call

• Product Updates: Kristalose saw additional states add it to Medicaid plans; Sancuso had new patient programs and expanded oncology sales; Vibativ is impacted by hurricane-related issues but has international launch plans; Caldolor had a new real-world outcomes study showing reduced adverse reactions; CET is working on new products like a delirium treatment with Phase 2 results and a GI imaging product in partnership.
• Organizational: Sales team has 50 individuals in customer-facing roles across three divisions (hospital, field sales, oncology) with co-promotional partnerships for Kristalose; new manufacturing/distribution partner for Vaprisol.
• Financial: Balance sheet as of September ended had $77 million in total assets, $17.5 million in cash and investments, $52 million in total liabilities, and $25 million in shareholders' equity; operating expenses improved year-to-date; continued share repurchase program.

For the three months ended September 30, 2024, net revenue from continuing operations was $9.1 million. Net revenue by product for the third quarter was $3.6 million for Kristalose, $2.6 million for Sancuso, $1.3 million for Caldolor, and $1 million for Vibativ. Year-to-date net revenues were $27 million, with product revenues totaling $10.9 million for Kristalose, $6.6 million for Sancuso, $5.1 million for Vibativ, and $3.6 million for Caldolor. Gross margin improved during the quarter to 85%.

• Shipments of brands are typically strongest in the fourth quarter and the company looks forward to reporting full year performance.
• Active acquisition initiative underway to seek select FDA-approved brands to add to the portfolio.

• Factors like natural disasters, economic downturns, public health epidemics, international conflicts that could affect future results; risks related to product launches, regulatory approvals, and market competition.